Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSeeing Machines Regulatory News (SEE)

Share Price Information for Seeing Machines (SEE)

Share Price is delayed by 15 minutes
Get Live Data
4.60    -0.05 (-1.08%)
Bid:
4.55
Ask:
4.615
Spread: 0.065 (1.429%)
Market Cap: £220.78m
SEE Live PriceLast checked at - London Stock Exchange

Intraday Seeing Machines Share Chart

1st Glaucoma Trial Completion

10 Jan 2006 09:18

Seeing Machines Limited10 January 2006 10 January 2006 SEEING MACHINES LIMITED ("Seeing Machines" or "the Company") NON -CONTACT OBJECTIVE GLAUCOMA DEVICE SUCCESSFULLY COMPLETES FIRST MAJOR CLINICAL TRIAL Seeing Machines Limited (AIM : SEE), a leading developer of advanced computerbased imaging software systems, announces the completion of the first majorclinical trial of its new groundbreaking technology for objective detection andmanagement of glaucoma, the group of eye diseases that affect peripheral vision,often leading to permanent loss of vision. Seeing Machines is developing a new medical device that assists clinicians todiagnose and manage disorders of the human visual system, particularly glaucoma. This recent trial has demonstrated with meaningful clinical utility, that thetechnology, as it stands today: • successfully detects the loss of visual field associated withglaucoma, and • successfully differentiates between those patients with visual fieldloss and those without, thus providing the basis for a reliable and accuratediagnostic instrument. Furthermore the trial has demonstrated significant opportunities for greatlyimproving the performance of the technology from the base-line used in thistrial. Commenting on the trial, Nick Cerneaz, Chief Executive of Seeing Machines said: "The technical progress demonstrated in this trial has assisted Seeing Machinesin reaching a key milestone of our entire medical device development program.Our scientific teams, led by Drs. Ted Maddess and Andrew James from theAustralian National University, have done a tremendous job so far and we are nowwell advanced in the development work arising from this trial. The preparationsfor the next major clinical trial aimed at testing these developments are wellunderway with an anticipated start date this quarter. We are very excited aboutthese results and keen to build further on them as we pursue our goal ofdelivering the world's first non-contact objective test for glaucoma." Enquiries:Seeing Machines Limited Insinger de Beaufort Parkgreen CommunicationsNick Cerneaz, CEO Simon Fox Justine Howarth / Victoria Thomas+61 (0) 2 6125 6501 +44 (0) 20 7190 7018 +44 (0) 20 7493 3713www.seeingmachines.com This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
7th Jun 201811:00 amRNSPrice Monitoring Extension
5th Jun 201811:05 amRNSSecond Price Monitoring Extn
5th Jun 201811:00 amRNSPrice Monitoring Extension
4th Jun 20187:00 amRNSAutomotive design win with US OEM for FOVIO chip
21st May 20187:00 amRNSBusiness Outlook Update
18th May 201810:14 amRNSEuropean Commission Agenda Affirms SEE Tech
17th May 20184:40 pmRNSSecond Price Monitoring Extn
17th May 20184:35 pmRNSPrice Monitoring Extension
16th May 20187:00 amRNSAustralian Distributor Expands Guardian Commitment
9th May 20184:40 pmRNSSecond Price Monitoring Extn
9th May 20184:35 pmRNSPrice Monitoring Extension
26th Apr 20187:08 amRNSAutomotive Design Award with Premium German OEM
12th Apr 20187:00 amRNSChange of Adviser
12th Mar 20187:00 amRNSHalf Year Results to 31 December 2017
9th Mar 20187:52 amRNSStatement regarding Press Speculation
28th Feb 20187:00 amRNSNotice of Results & Investor Events
22nd Feb 20188:13 amRNSHolding(s) in Company
22nd Feb 20188:00 amRNSBlock Listing Cancellation
21st Feb 20189:00 amRNSDirectorate Change Update
8th Feb 20187:00 amRNSTrading Update & Fleet, Rail and Off-Road Update
29th Jan 20187:00 amRNSDirectorate Change
23rd Jan 201810:54 amRNSHolding(s) in Company
16th Jan 20189:22 amRNSResult of Offer and Total Voting Rights
9th Jan 201810:44 amRNSHolding(s) in Company
8th Jan 20189:23 amRNSHolding(s) in Company
3rd Jan 20188:44 amRNSResult of General Meeting and Total Voting Rights
22nd Dec 20177:00 amRNSBlock Listing Return and Total Voting Rights
5th Dec 20173:57 pmRNSSuccessful Placing and Subscriptions to raise £35m
4th Dec 20175:33 pmRNSProposed Accelerated Bookbuild
30th Nov 20177:00 amRNSDubai Distributor Wins Guardian Contracts in 2017
17th Nov 20177:01 amRNSResult of AGM
17th Nov 20177:00 amRNSAGM Statement
2nd Nov 201710:02 amRNSIssue of Shares to Directors and Staff & TVR
30th Oct 20177:00 amRNSNew DMS Program Award
25th Oct 20179:00 amRNSHolding(s) in Company
25th Oct 20177:00 amRNSEmirates and Seeing Machines Collaboration
24th Oct 20177:00 amRNSEuro NCAP and NTSB - Driver Monitoring Systems
23rd Oct 20177:00 amRNSNotice of AGM
17th Oct 201712:40 pmRNSBusiness Outlook Update
10th Oct 20179:56 amRNSHolding(s) in Company
10th Oct 20177:00 amRNSGM 2018 Cadillac CT6 Super Cruise System
11th Sep 20177:00 amRNSFinal Results
8th Sep 201712:10 pmRNSNotice of Results
8th Sep 20177:00 amRNSGlobal Agreement with Progress Rail
23rd Aug 201710:37 amRNSHolding(s) in Company
17th Aug 20177:00 amRNSAutoliv Driver Monitoring Systems
15th Aug 20179:36 amRNSFleet Partnership Agreement with Geotab
11th Aug 201712:03 pmRNSHolding(s) in Company
8th Aug 20177:00 amRNSTrading Update
31st Jul 20177:00 amRNSDirectorate Change

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.